Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing